Listing of mondoBIOTECH on the SIX Swiss Exchange
As of 26 August 2009, the common shares of mondoBIOTECH are listed on the SIX Swiss Exchange. mondoBIOTECH analyses peptides that are naturally occurring in the human body in order to identify promising candidates for the development of medicinal products for use in the treatment of rare and neglected diseases.
Lenz & Staehelin advised mondoBIOTECH in its listing and also acted as listing agent. The team was led by Patrick Schleiffer and included Damian Fischer, Philippe Teuscher and Nadine Strub.